The risk of adverse obstetric outcomes is elevated in women who conceive while using an intrauterine device (IUD), especially in women who retain the device throughout pregnancy, according to a study in the October issue of the American Journal of Obstetrics & Gynecology.
Users at conception have a higher risk of preterm delivery and chorioamnionitis than nonusers
THURSDAY, Oct. 1 (HealthDay News)-The risk of adverse obstetric outcomes is elevated in women who conceive while using an intrauterine device (IUD), especially in women who retain the device throughout pregnancy, according to a study in the October issue of the
American Journal of Obstetrics & Gynecology.
Hadas Ganer, of Ben Gurion University of the Negev in Be'er-Sheva, Israel, and colleagues compared pregnancy outcomes in 98 women with a retained IUD, 194 women with an IUD removed in early pregnancy, and 141,191 women without an IUD.
The researchers found that the rate of preterm delivery was significantly higher in the retained-IUD and removed-IUD groups (18.4 and 14.4 percent, respectively) than in the no-IUD group (7.3 percent). They also found that the rate of chorioamnionitis was significantly higher in the two IUD groups (7.1 and 4.1 percent, respectively) than in the no-IUD group (0.7 percent).
"Women conceiving with an IUD should be informed regarding these outcomes because IUD removal reduces the risk for adverse obstetric outcomes, but does not eliminate it," the authors conclude. "Careful surveillance of high-risk pregnancies is warranted, as well as neonatal surveillance in the case of preterm and chorioamnionitic deliveries."
Abstract
SART data indicates rise in IVF use in 2022
April 24th 2024Dive into the latest statistics from the Society for Assisted Reproductive Technology, revealing a 6% increase in in vitro fertilization cycles and a surge in egg freezing, amidst a landscape of rising fertility service demand and evolving clinical practices.
Read More
Hormone therapy safety: Study finds potential benefits for senior women
April 24th 2024A recent large-scale study challenged age-related concerns, suggesting hormone therapy may offer safety and even benefits for menopausal women aged over 65 years, aligning with The Menopause Society's 2022 Position Statement.
Read More